Smith & Nephew plc (LON: SN)
London
· Delayed Price · Currency is GBP · Price in GBp| Market Cap | 8.50B |
| Revenue (ttm) | 4.46B |
| Net Income (ttm) | 241.34M |
| Shares Out | 871.98M |
| EPS (ttm) | 0.28 |
| PE Ratio | 35.30 |
| Forward PE | 13.53 |
| Dividend | 0.30 (3.04%) |
| Ex-Dividend Date | Oct 3, 2024 |
| Volume | 1,495,289 |
| Open | 982.00 |
| Previous Close | 974.80 |
| Day's Range | 971.00 - 983.40 |
| 52-Week Range | 911.00 - 1,245.26 |
| Beta | 0.63 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 7, 2024 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other... [Read more]
Financial Performance
In 2023, Smith & Nephew's revenue was $5.55 billion, an increase of 6.40% compared to the previous year's $5.22 billion. Earnings were $263.00 million, an increase of 17.94%.
Financial numbers in USD Financial StatementsNews
Big investors call for break-up of Smith & Nephew, FT reports
Three major investors are pushing medical device maker Smith & Nephew to consider a break-up of the business, the Financial Times reported on Thursday, citing shareholders.
Big investors call for break-up of Smith & Nephew
Medical devices company should consider spinning off orthopaedics unit, say three top-20 shareholders
Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends
Smith & Nephew investors may push for breakup - Mail on Sunday
Shareholders of Smith & Nephew (SNN) may push for a breakup if CEO Deepak Nath fails to improve performance, particularly in the orthopaedics division.
Smith & Nephew falls as Berenberg downgrades to Hold
Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript
Smith & Nephew plc (NYSE:SNN) Q3 2024 Earnings Conference Call October 31, 2024 4:30 AM ETCompany ParticipantsDeepak Nath - CEO & DirectorJohn...
MARKET REPORT: Smith & Nephew rocked by slowdown in China
Smith & Nephew anticipates full-year sales growth of 4.5%, not 5% to 6%. Sales in the third-quarter were up 4% - or 5.9% excluding China - to £1.1bn.
Smith & Nephew stock slumps after China-tied profit warning
Three Quick Facts: Smith & Nephew, Shell and Spectris
Shell profits beat expectations after higher gas sales, Smith & Nephew profit margins trimmed and headwinds set to drag at Spectris
Smith & Nephew slashes annual revenue forecast on weak China
British medical equipment maker Smith & Nephew cut its annual underlying revenue growth forecast on Thursday to 4.5% from the previous outlook range of 5% to 6%, primarily hurt by challenges in its su...
RENASYS™ EDGE Negative Pressure Wound Therapy System wins Red Dot Award for Design
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, is proud to announce that its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System has won the Red Dot Award for Design ...
Smith+Nephew partners with JointVue™ for Ultrasound preoperative planning in robotics-assisted surgery
Patented technology further personalizes total knee arthroplasty for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed a co-ma...
Smith & Nephew goes ex dividend tomorrow
Smith & Nephew plc goes ex dividend tomorrow
This stock is 'boring' but has 'fantastic' risk-reward: Scharf
Eric Lynch from Scharf Investments explains why he likes the non-tech and utilities sectors.
First cases using Smith+Nephew's new CATALYSTEM™ Primary Hip System completed; surgeons hail precision, efficiency and reproducibility
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces promising surgeon feedback from the first completed cases utilizing its new CATALYSTEM Primary Hip System. Desig...
Smith+Nephew brings pre-operative planning and accuracy to total ankle replacement with new TOTAL ANKLE Patient-Matched Guides
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its TOTAL ANKLE Patient-Matched Guides, giving surgeons a predictable and efficient option to help...
Smith & Nephew Delivering On Its Turnaround Promise
Explore Smith & Nephew's turnaround progress in the ortho business, potential for margin growth, and management's key focus for future success.
Smith & Nephew plc (SNN) Q2 2024 Earnings Call Transcript
Smith & Nephew shares rise as profit beats market forecast
Smith & Nephew's shares rose 9% on Thursday after the British medical equipment maker's half-year profit beat market forecast, helped by a strong performance in its orthopaedics segment.
Activist Cevian has a stake in Smith & Nephew. How it may help improve margins
British company Smith & Nephew is already a global leader in medical tech. Cevian could help it boost its profitability.
What's Driving Smith & Nephew PLC's Surprising 10% Stock Rally?
What's Driving Smith & Nephew PLC's Surprising 10% Stock Rally?
Activist Investor Takes Stake In Sports Medicine Player Smith & Nephew, Shares Surge
Shares of Smith & Nephew Plc SNN are trading higher on Friday. Smith+Nephew offers a medical technology portfolio across orthopedics, sports medicine, ENT, and advanced wound management.
Activist Investor Takes Stake In Sports Medicine Player Smith & Nephew, Shares Surge
Shares of Smith & Nephew Plc (NYSE: SNN) are trading higher on Friday. Smith+Nephew offers a medical technology portfolio across orthopedics, sports medicine, ENT, and advanced wound management. In a...